Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 46, 2015, Pages 14331-14336

  Dolcetti, Riccardo ^a   Giagulli, Cinzia ^b   He, Wangxiao ^c   Selleri, Marina ^d   Caccuri, Francesca ^b   Eyzaguirre, Lindsay M ^e   Mazzuca, Pietro ^b   Corbellini, Silvia ^b   Campilongo, Federica ^b   Marsico, Stefania ^f   Giombini, Emanuela ^d   Muraro, Elena ^a   Rozera, Gabriella ^d   De Paoli, Paolo ^a   Carbone, Antonino ^a   Capobianchi, Maria Rosaria ^d   Ippolito, Giuseppe ^d   Fiorentini, Simona ^b   Blattner, William A ^e   Lu, Wuyuan ^c,e   Gallo, Robert C ^e   Caruso, Arnaldo ^b   more..

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALABRIA   (Italy)

Author keywords

AIDS; B cell clonogenicity; HIV 1 matrix protein p17; Non Hodgkin lymphoma; p17 variants

Indexed keywords

ALANINE; ASPARAGINE; GLYCINE; HUMAN IMMUNODEFICIENCY VIRUS 1 MATRIX PROTEIN P17; MATRIX PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; B CELL LYMPHOMA; CIRCULAR DICHROISM; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PYROSEQUENCING; SIGNAL TRANSDUCTION; TUMOR BIOPSY; X RAY CRYSTALLOGRAPHY; ADULT; B LYMPHOCYTE; CLINICAL TRIAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VIRUS CELL TRANSFORMATION;

ADULT; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84947604145     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1514748112     Document Type: Article

References (32)

1. Shiels MS, et al. (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753-762.
2. Vandenhende MA, et al.; ANRS EN20 Mortalité 2010 study group (2015) Cancerrelated causes of death among HIV-infected patients in France in 2010: Evolution since 2000. PLoS One 10(6):e0129550.
3. Coté TR, et al.; AIDS/Cancer Study Group (1997) Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burden. Int J Cancer 73(5):645-650.
4. Gloghini A, Dolcetti R, Carbone A (2013) Lymphomas occurring specifically in HIV-infected patients: From pathogenesis to pathology. Semin Cancer Biol 23(6):457-467.
5. Knowles DM (2003) Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 17(3):785-820.
6. Epeldegui M, Vendrame E, Martínez-Maza O (2010) HIV-associated immune dysfunction and viral infection: Role in the pathogenesis of AIDS-related lymphoma. Immunol Res 48(1-3):72-83.
7. Martínez-Maza O, Breen EC (2002) B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 14(5):528-532.
8. Da Silva SR, De Oliveira DE (2011) HIV, EBV and KSHV: Viral cooperation in the pathogenesis of human malignancies. Cancer Lett 305(2):175-185.
9. He B, et al. (2006) HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 176(7):3931-3941.
10. Kundu RK, et al. (1999) Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood 94(1):275-282.
11. Freed EO (1998) HIV-1 gag proteins: Diverse functions in the virus life cycle. Virology 251(1):1-15.
12. Curreli S, et al. (2013) B cell lymphoma in HIV transgenic mice. Retrovirology 10:92.
13. Giagulli C, et al. (2011) Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 6(3):e17831.
14. Caccuri F, et al. (2014) Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol 88(10):5706-5717.
15. Giombini E, et al. (2014) Detection of HIV-1 matrix protein p17 quasispecies variants in plasma of chronic HIV-1-infected patients by ultra-deep pyrosequencing. J Acquir Immune Defic Syndr 66(3):332-339.
16. Popovic M, et al. (2005) Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 102(41):14807-14812.
17. Jiang BH, Liu LZ (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784(1):150-158.
18. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96(8):4240-4245.
19. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI (1996) Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly. Proc Natl Acad Sci USA 93(7):3099-3104.
20. Chakrabartty A, Kortemme T, Baldwin RL (1994) Helix propensities of the amino acids measured in alanine-based peptides without helix-stabilizing side-chain interactions. Protein Sci 3(5):843-852.
21. Koepf EK, Petrassi HM, Sudol M, Kelly JW (1999) WW: An isolated three-stranded antiparallel beta-sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state. Protein Sci 8(4):841-853.
22. Taylor JG, Liapis K, Gribben JG (2015) The role of the tumor microenvironment in HIV-associated lymphomas. Biomarkers Med 9(5):473-482.
23. Martorelli D, et al. (2015) A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. Int J Cancer 137(6):1374-1385.
24. Goh GK, Dunker AK, Uversky VN (2008) A comparative analysis of viral matrix proteins using disorder predictors. Virol J 5:126.
25. Caccuri F, et al. (2012) HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci USA 109(36):14580-14585.
26. Basta D, et al. (2015) Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. Pathog Dis 73(8): ftv062.
27. Caccuri F, et al. (2014) HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis. Arterioscler Thromb Vasc Biol 34(4):846-856.
28. Pepper MS, Tille JC, Nisato R, Skobe M (2003) Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314(1):167-177.
29. Pratesi C, et al. (2015) γ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation. PLoS One 10(2):e0116887.
30. De Francesco MA, et al. (2002) HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci USA 99(15):9972-9977.
31. Li W, Godzik A (2006) Cd-hit: A fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22(13):1658-1659.
32. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4(11):2411-2423.